Explore the 2022 IKCS: Europe Program by Day

Download the PDF Program Booklet

Abstract Titles Now Available! View Abstract Titles

Friday 22 April
SessionsTimeSpeaker
Registration Open6:30 AM- 4:30 PM
Poster and Exhibit Hall Open6:30 AM5:15 PM
Networking Session: Meet the Experts Breakfast7:00 AM- 7:50 AMMeet Kidney Cancer Experts from across Europe to meet new people and make lasting connections with colleagues. Faculty experts will be seated at tables with specific topics. Pick a table and join the conversation!

Advocacy: Michael Staehler, MD, PhD
Career Paths Outside Academia: Lisa Pickering, MD, PhD
Oncology: Guillermo de Velasco, MD, PhD
Publications and Getting Published: Camillo Porta, MD
Research and Clinical Trial Funding: Gabriel Malouf, MD, PhD and Samra Turajlic, PhD, MBBS, MRCP
Urology: Lars Lund, MD, PhD
Break7:50 AM- 8:00 AM
Welcome and Session 1: Surgical Approaches8:00 AM- 9:15 AMChair/Moderator: Christian Beisland, MD, PhD
Meeting Welcome8:00 AM- 8:05 AMSamra Turajlic, PhD, MBBS, MRCP
The New WHO Classification8:05 AM- 8:20 AMHolger Moch, MD
Risk Classification of Renal Tumors & How to Optimize Future TMN Classification8:20 AM- 8:35 AMUmberto Capitanio, MD
Selecting Patients for Adjuvant Therapy8:35 AM- 8:50 AMAxel Bex, MD, PhD
Perioperative Indications for Systemic Therapy8:50 AM- 9:05 AMTian Zhang, MD, MHS
Panel Discussion and Question and Answer9:05 AM- 9:15 AM
Session 2: Oral Abstract Session9:15 AM- 10:10 AMMichael Staehler, MD, PhD
Abstract 1: Nivolumab plus ipilimumab plus cabozantinib for previously untreated advanced renal cell carcinoma: Results from a discontinued study arm of CheckMate 9ER9:15 AM- 9:25 AMBernard Escudier, MD
Abstract 2: Relevance of items in the FACT Kidney Cancer Symptom Inventory-19 (FKSI-19): Results of a patient survey9:25 AM- 9:35 AMCristiane Bergerot, PhD
Abstract 3: A systematic review of heterogeneity in outcome reporting, definition and measurement in localised kidney cancer.9:35 AM- 9:45 AMKatharina Beyer, BSc, MSc
Abstract 4: ‘Real world’ impact of immune checkpoint inhibitors (ICI) on survival in metastatic renal cell cancer (mRCC)9:45 AM- 9:55 AMWill Ince, FRCR, MRCP, MRCGP, MB BS
Panel Discussion and Question and Answer9:55 AM- 10:10 AM
Break10:10 AM- 10:25 AM
Session 3: Keynote10:25 AM- 11:10 AMChair/Moderator: Samra Turajlic, PhD, MBBS, MRCP
Keynote Lecture: Learning From the Extreme: Challenges in the Surgical Management of Locally Advanced and Recurrent Disease10:25 AM- 10:55 AMTim O’Brien, MA, DM, FRCS (Urol)
Discussion and Question and Answer10:55 AM- 11:10 AM
Session 4: Caring for the Whole Patient: Non-clinical Considerations11:10 AM- 12:15 PMChair/Moderator: Daniel J. George, MD
Misinformation and Disinformation11:10 AM- 11:20 AMDena Battle
Cost in Renal Cell Carcinoma11:20 AM- 11:30 AMMichael Staehler, MD, PhD
Psychosocial Implications of Cancer11:30- 11:40 AMDésirée Louise Dräger, MD
Quality of Life After Renal Cell Carcinoma Treatment11:40 AM- 11:50 AMTheresa Junker, RN, PhD
The Role of Advocacy in Patient Care11:50 AM- 12:00 PMRachel Giles, MD
Panel Discussion and Question and Answer12:00 PM- 12:15 PM
Lunch and Poster Session 12:15 PM- 2:15 PMView Abstract Titles
Non-CME Industry Sponsored Symposium: Evolving Strategies for Early-Stage Renal Cell Carcinoma: The Emerging Role of Immuno-Oncology (Bristol Myers Squibb)12:45 PM- 1:45 PM
Session 5: Systemic Therapy Debate: Selecting First-line Therapy2:15 PM- 3:15 PMChair/Moderator: Gillermo de Velasco, MD, PhD
Debate: In Favor of IO/TKI2:15 PM- 2:25 PMLisa Pickering, MD, PhD
Debate: In Favor of IO/IO2:25 PM- 2:35 PMAristotelis Bamias, MD
Clinical Cases with Discussion2:35 PM- 3:00 PM
Panel Question and Answer3:00 PM- 3:15 PM
Session 6: Systemic Therapy Debate: Later-line Therapy3:15 PM- 4:15 PMChair/Moderator: Viktor Grünwald, MD, PhD
Clinical Cases 3:15 PM- 3:20 PM
Debate: In Favor of Clinical Considerations and Challenges in Selecting Later-line Therapies3:20 PM- 3:30 PMLaurence Albiges, MD, PhD
Debate: In Favor of Evidence-based Treatment in the 2nd and 3rd Line3:30 PM- 3:40 PMCamillo Porta, MD
Discussion and Panel Question and Answer3:40 PM- 4:15 PM
Coming Together for Ukraine4:15 PM- 4:30 PMLaura Bukavina, MD, MPH
Networking Session: Evening Reception4:30 PM- 5:30 PMMingle with colleagues and make new connections with oncologists and urologists.
Networking Session: Poster Walks (In-person)4:30 PM- 5:15 PMLars Lund, MD, PhD
Networking Session: Poster Walks (Virtual)4:30 PM- 5:15 PMCristina Suárez Rodríguez, MD
Saturday 23 April
SessionsTimeSpeaker
Registration Open6:30 AM- 4:00 PM
Poster and Exhibit Hall Open6:30 AM- 4:00 PM
Networking Session: Women in RCC Breakfast7:00 AM- 7:50 AMLaurence Albiges, MD, PhD
Break7:50 AM- 8:00 AM
Session 7: The John Fitzpatrick Award and Lecture8:00 AM- 8:45 AMChair/Moderator: Axel Bex, MD, PhD
The John Fitzpatrick Award Lecture: Strategies to Improve the Management of Initially Localized Kidney Cancer8:00 AM- 8:30 AMGrant Stewart, MD
Discussion and Question and Answer8:30 AM- 8:45 AM
Session 8: Diagnostics and Screening8:45 AM- 9:45 AMChair/Moderator: Axel Bex, MD, PhD
Diagnostics and Screening: Current Status and Future Directions8:45 AM- 8:55 AMJose Karam, MD, FACS
Genetics: Assessment for Hereditary Renal Cell Carcinoma8:55 AM- 9:05 AMGennady Bratslavsky, MD
Updates and the Future of Histopathology in Renal Cell Carcinoma9:05 AM- 9:15 AMEva Comperat, MD, PhD
PET/CT in Renal Cancer9:15 AM- 9:25 AMOrhan Oz, MD
Management of Incidental Renal Masses: A Summary9:25 AM- 9:35 AMLars Lund, MD, PhD
Panel Discussion and Question and Answer9:35 AM- 9:45 AM
Break9:45 AM- 10:00 AM
Session 9: Basic Science in RCC10:00 AM- 11:00 AMChair/Moderator: Gabriel Malouf, MD
Abstract 5: SETD2 loss in kidney cancer – Setting the stage for synthetic lethality10:00 AM- 10:10 AMAguirre A. de Cubas, PhD
Animal Models and Immunotherapy10:10 AM- 10:20 AMIan Frew, PhD, BSc
Targeting Metabolism in RCC: More Than Just the Cancer Cells10:20 AM- 10:30 AMKaty Beckermann, PhD, MD
Modulating the RCC TME to Increase IO Efficacy10:30 AM- 10:40 AMCharles Drake, MD, PhD
Panel Discussion and Question and Answer10:40 AM- 11:00 AM
Session 10: Biomarker Breakdown11:00 AM- 12:00 PMChair/Moderator: Bernard Escudier, MD
Biomarker Discovery Through TCR Sequencing11:00 AM- 11:10 AMSamra Turajlic, PhD, MBBS, MRCP
Biomarker Discovery Through Single-cell RNA Sequencing11:10 AM- 11:20 AMDavid Braun, MD, PhD
Vaccines and Cellular Therapies11:20 AM- 11:30 AMElfriede Nößner, PhD
What’s Next? Overcoming Primary and Secondary Resistance to ICI11:30 AM- 11:40 AMJohn Haanen, MD, PhD
Panel Discussion and Question and Answer11:40 AM- 12:00 PM
Lunch and Poster Session12:00 PM- 2:00 PMView Abstract Titles
Session 11: The Role of Radiation Therapy in the Management of Renal Cell Carcinoma2:00 PM- 2:45 PMChair/Moderator: Lars Lund, MD, PhD
Radiation Therapy in the Treatment of Renal Cell Carcinoma2:00 PM- 2:10 PMStephanie Kroeze, MD, PhD
Radiation vs Non-radiation: Treatment of Brain Metastases2:10 PM- 2:20 PMRonan Flippot, MD, MSc
Radiation in the Management of Oligotmetastatic Disease2:20 PM- 2:30 PMMarta Scorsetti, MD
Panel Discussion and Question and Answer2:30 PM- 2:45 PM
Session 12: WoodFire®
WoodFire® is an exciting chance to watch clinicians debate the various treatment options for each presented oncology case. It’s the fiercest tumor board you’ll ever see!
2:45 PM- 4:00 PM
Case Presentation and Discussion 12:45 PM- 3:00 PMLaurence Albiges, MD, PhD
Case Presentation and Discussion 23:00 PM- 3:15 PMChristian Beisland, MD, PhD
Case Presentation and Discussion 33:15 PM- 3:30 PMPedro Barata, MD, MSc
Case Presentation and Discussion 43:30 PM- 3:45 PMGennady Bratslavsky, MD
Panel Question and Answer3:45 PM- 4:00 PM
Sunday 24 April
SessionsTimeSpeaker
Registration Open7:00 AM- 8:30 AM
Poster and Exhibit Hall Open7:00 AM- 10:00 AM
Session 13: The Pieter de Mulder Award and Lecture8:00 AM- 8:45 AMChair/Moderator: Thomas Powles, MBBS, MRCP, MD
The Pieter de Mulder Award Lecture8:00 AM- 8:30 AMLaurence Albiges, MD, PhD
Discussion and Question and Answer8:30 AM- 8:45 AM
Session 14: Selecting Therapy for Non-clear cell Renal Cell Carcinoma Subtypes8:45 AM- 9:55 AMChair/Moderator: Bernard Escudier, MD
Gene Expression Profiling of nccRCC Identifies a Unique Spectrum of Transcriptional Signatures with Potential Clinical Relevance8:45 AM- 8:55 AMPedro Barata, MD, MSc
Translocation RCC8:55 AM- 9:05 AMGabriel Malouf, MD, PhD
Chromophobe RCC9:05 AM- 9:15 AMElizabeth P. Henske, MD
Collecting Duct and Renal Medullary Carcinoma9:15 AM- 9:25 AMGiuseppe Procopio, MD
Papillary Renal Cell Carcinoma9:25 AM- 9:35 AMGuillermo de Velasco, MD, PhD
Panel Discussion and Question and Answer9:35 AM- 9:55 AM
Session 15: Therapeutic Management: Research in the RCC Landscape9:55 AM- 10:40 AMChair/Moderator: Thomas Powles, MBBS, MRCP, MD
Withholding Therapy: Wrongful Doing or Chance for Success in Immunotherapy? 9:55 AM- 10:10 AMNaveen Vasudev, MBChB, MRCP, PhD
Optimizing Treatment Schedules with TKI Therapy10:10 AM- 10:25 AMJanet Brown, BMedSci, MBBS, MSc, MD, FRCP
Panel Discussion and Question and Answer10:25 AM- 10:40 AM
Closing and Meeting Adjournment10:40 AM- 10:50 AMMichael Staehler, MD, PhD